These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 24859205

  • 1. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology.
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
    Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P, PETACC8 investigators.
    Clin Cancer Res; 2018 Oct 01; 24(19):4745-4753. PubMed ID: 29921730
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
    Symonds L, Yu M, Zhang Y, Ou FS, Zemla TJ, Carter K, Bertagnolli M, Innocenti F, Bosch LJ, Meijer GA, Carvalho B, Grady WM, Cohen SA.
    Epigenetics; 2022 Dec 01; 17(12):1715-1725. PubMed ID: 35412430
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.
    Clin Colorectal Cancer; 2016 Jun 01; 15(2):164-9. PubMed ID: 26702772
    [Abstract] [Full Text] [Related]

  • 5. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.
    J Clin Oncol; 2009 Apr 10; 27(11):1814-21. PubMed ID: 19273709
    [Abstract] [Full Text] [Related]

  • 6. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
    Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.
    Virchows Arch; 2007 May 10; 450(5):529-37. PubMed ID: 17372756
    [Abstract] [Full Text] [Related]

  • 7. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás-Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A.
    Gastroenterology; 2011 Apr 10; 140(4):1174-81. PubMed ID: 21185836
    [Abstract] [Full Text] [Related]

  • 8. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.
    Clin Cancer Res; 2012 Feb 01; 18(3):890-900. PubMed ID: 22147942
    [Abstract] [Full Text] [Related]

  • 9. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
    Int J Cancer; 2013 May 01; 132(9):2209-16. PubMed ID: 23034738
    [Abstract] [Full Text] [Related]

  • 10. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
    Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, Alliance for Clinical Trials in Oncology.
    J Natl Cancer Inst; 2013 Dec 04; 105(23):1789-98. PubMed ID: 24231454
    [Abstract] [Full Text] [Related]

  • 11. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
    Gastroenterology; 2015 Jan 04; 148(1):88-99. PubMed ID: 25305506
    [Abstract] [Full Text] [Related]

  • 12. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
    Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Maizels N.
    PLoS One; 2014 Jan 04; 9(10):e108483. PubMed ID: 25310185
    [Abstract] [Full Text] [Related]

  • 13. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
    JAMA Oncol; 2017 Apr 01; 3(4):472-480. PubMed ID: 28006055
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G.
    BMC Med; 2011 Jan 31; 9():10. PubMed ID: 21281463
    [Abstract] [Full Text] [Related]

  • 15. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 16. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.
    BMC Cancer; 2011 Aug 10; 11():344. PubMed ID: 21827707
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 18. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology.
    Clin Cancer Res; 2014 Jun 01; 20(11):3033-43. PubMed ID: 24687927
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
    Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D.
    J Clin Oncol; 2009 Jul 01; 27(19):3117-25. PubMed ID: 19451425
    [Abstract] [Full Text] [Related]

  • 20. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
    Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C.
    Int J Clin Oncol; 2016 Dec 01; 21(6):1091-1101. PubMed ID: 27435270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.